Current Report Filing (8-k)
01 Outubro 2021 - 6:20PM
Edgar (US Regulatory)
0001022899
false
Protagenic Therapeutics, Inc.new
--12-31
0001022899
2021-09-29
2021-09-29
0001022899
us-gaap:CommonStockMember
2021-09-29
2021-09-29
0001022899
PTIX:CommonStockWarrantsMember
2021-09-29
2021-09-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported):
|
September
29, 2021
|
PROTAGENIC
THERAPEUTICS, INC.
|
(Exact
name of Company as specified in its charter)
|
Delaware
|
|
000-51353
|
|
06-1390025
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
149
Fifth Avenue, Suite 500, New York, NY
|
|
10010
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
212-994-8200
|
|
|
(Company’s
telephone number, including area code)
|
|
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Ticker
symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
PTIX
|
|
Nasdaq
|
Common
Stock Warrants
|
|
PTIXW
|
|
Nasdaq
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Exchange Act of 1934.
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
See
Item 5.07 below with respect to the filing of the Classified Board Amendment (defined below) to the Company’s Third Amended and
Restated Certificate of Incorporation.
Item
5.07. Submission of Matters to a Vote of Security Holders.
Protagenic
Therapeutics, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”)
on September 29, 2021. Holders of an aggregate of 16,779,149 shares of the Company’s Common Stock at the close of business on August
24, 2021 were entitled to vote at the Annual Meeting, of which 10,611,130 shares were present in person or represented by proxy. At the
Annual Meeting, the Company’s stockholders voted as follows:
Proposal
One: The stockholders elected each of the following individuals as a director to serve their current terms until the Company’s
2022 Annual Meeting of Stockholders, at which point the classified board structure will go into effect, as described by the Classified
Board Amendment (defined below).
Name
|
|
For
|
|
|
Against
|
|
|
Withheld
|
|
|
Broker
Non-Votes
|
|
Garo H. Armen
|
|
|
8,877,968
|
|
|
|
-
|
|
|
|
102,438
|
|
|
|
1,630,724
|
|
Robert B. Stein
|
|
|
8,877,773
|
|
|
|
-
|
|
|
|
102,633
|
|
|
|
1,630,724
|
|
Khalil Barrage
|
|
|
8,856,335
|
|
|
|
-
|
|
|
|
124,071
|
|
|
|
1,630,724
|
|
Brian J. Corvese
|
|
|
8,857,135
|
|
|
|
-
|
|
|
|
123,271
|
|
|
|
1,630,724
|
|
Joshua Silverman
|
|
|
8,367,762
|
|
|
|
-
|
|
|
|
612,644
|
|
|
|
1,630,724
|
|
Jennifer Buell
|
|
|
8,857,230
|
|
|
|
-
|
|
|
|
123,176
|
|
|
|
1,630,724
|
|
Proposal
Two: The stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation to
classify our Board of Directors into three classes with staggered three-year terms (the “Classified Board Amendment”).
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker Non-Votes
|
|
|
8,824,972
|
|
|
|
150,884
|
|
|
|
4,550
|
|
|
|
1,630,724
|
|
Following
the approval of the Classified Board Amendment by the Company’s stockholders at the Annual Meeting, the Classified Board Amendment
was filed with the Delaware Secretary of State on October 1, 2021. A copy of the Classified Board Amendment is attached to this Current
Report on Form 8-K as Exhibit 3.1, and is incorporated by reference herein.
As
a result of the filing Classified Board Amendment with the Delaware Secretary of State, members of the Company’s Board of Directors
will now be classified into three classes with staggered three-year terms (with the exception of the expiration of the initial Class
I and Class II directors), as follows:
Class
I , comprised of two directors, initially Jennifer Buell and Robert B. Stein (with their initial terms expiring at our 2022 annual
meeting of stockholders and members of such class serving successive three-year terms);
Class II , comprised of two directors, initially Khalil Barrage and Joshua Silverman (with their initial terms expiring at our 2023 annual meeting of stockholders and members of such class serving successive three-year terms); and
Class III , comprised of two directors, initially Garo H. Armen and Brian J. Corvese (with their initial terms expiring at our 2024 annual meeting of stockholders and members of such class serving successive three-year terms).
Proposal
Three: The stockholders ratified the selection of MaloneBailey LLP as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2021.
For
|
|
|
Against
|
|
|
Abstain
|
|
|
10,602,842
|
|
|
|
2,807
|
|
|
|
5,481
|
|
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
PROTAGENIC
THERAPEUTICS, INC.
|
|
|
|
Date:
October 1, 2021
|
By:
|
/s/
Alexander K. Arrow
|
|
Name:
|
Alexander
K. Arrow
|
|
Title:
|
Chief
Financial Officer
|
Protagenic Therapeutics (NASDAQ:PTIX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Protagenic Therapeutics (NASDAQ:PTIX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025